Tags

Type your tag names separated by a space and hit enter

Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients.
Chest. 2013 Jul; 144(1):226-233.Chest

Abstract

BACKGROUND

Long-term survival after lung transplant is limited by the development of chronic and progressive airflow obstruction, a condition known as bronchiolitis obliterans syndrome (BOS). While prior studies strongly implicate cellular rejection as a strong risk factor for BOS, less is known about the clinical significance of human leukocyte antigen (HLA) antibodies and donor HLA-specific antibodies in long-term outcomes.

METHODS

A single-center cohort of 441 lung transplant recipients, spanning a 10-year period, was prospectively screened for HLA antibodies after transplant using flow cytometry-based methods. The prevalence of and predictors for HLA antibodies were determined. The impact of HLA antibodies on survival after transplant and the development of BOS were determined using Cox models.

RESULTS

Of the 441 recipients, 139 (32%) had detectable antibodies to HLA. Of these 139, 54 (39%) developed antibodies specific to donor HLA. The detection of posttransplant HLA antibodies was associated with BOS (HR, 1.54; P=.04) and death (HR, 1.53; P=.02) in multivariable models. The detection of donor-specific HLA antibodies was associated with death (HR, 2.42; P<.0001). The detection of posttransplant HLA antibodies was associated with pretransplant HLA-antibody detection, platelet transfusions, and the development of BOS and cytomegalovirus pneumonitis.

CONCLUSIONS

Approximately one-third of lung transplant recipients have detectable HLA antibodies, which are associated with a worse prognosis regarding graft function and patient survival.

Authors+Show Affiliations

Department of Medicine, Duke University, Durham, NC. Electronic address: laurie.snyder@dm.duke.edu.Department of Medicine, Duke University, Durham, NC.Department of Pathology, Duke University, Durham, NC.Department of Pediatrics and Medical Genetics Research Institute, Cedars-Sinai Health Systems, Los Angeles, CA.Department of Medicine, Duke University, Durham, NC.Department of Medicine, Duke University, Durham, NC.Department of Medicine, Duke University, Durham, NC.Department of Medicine, Duke University, Durham, NC.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

23328795

Citation

Snyder, Laurie D., et al. "Implications for Human Leukocyte Antigen Antibodies After Lung Transplantation: a 10-year Experience in 441 Patients." Chest, vol. 144, no. 1, 2013, pp. 226-233.
Snyder LD, Wang Z, Chen DF, et al. Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest. 2013;144(1):226-233.
Snyder, L. D., Wang, Z., Chen, D. F., Reinsmoen, N. L., Finlen-Copeland, C. A., Davis, W. A., Zaas, D. W., & Palmer, S. M. (2013). Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest, 144(1), 226-233. https://doi.org/10.1378/chest.12-0587
Snyder LD, et al. Implications for Human Leukocyte Antigen Antibodies After Lung Transplantation: a 10-year Experience in 441 Patients. Chest. 2013;144(1):226-233. PubMed PMID: 23328795.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. AU - Snyder,Laurie D, AU - Wang,Ziwei, AU - Chen,Dong-Feng, AU - Reinsmoen,Nancy L, AU - Finlen-Copeland,C Ashley, AU - Davis,W Austin, AU - Zaas,David W, AU - Palmer,Scott M, PY - 2013/1/19/entrez PY - 2013/1/19/pubmed PY - 2013/10/1/medline SP - 226 EP - 233 JF - Chest JO - Chest VL - 144 IS - 1 N2 - BACKGROUND: Long-term survival after lung transplant is limited by the development of chronic and progressive airflow obstruction, a condition known as bronchiolitis obliterans syndrome (BOS). While prior studies strongly implicate cellular rejection as a strong risk factor for BOS, less is known about the clinical significance of human leukocyte antigen (HLA) antibodies and donor HLA-specific antibodies in long-term outcomes. METHODS: A single-center cohort of 441 lung transplant recipients, spanning a 10-year period, was prospectively screened for HLA antibodies after transplant using flow cytometry-based methods. The prevalence of and predictors for HLA antibodies were determined. The impact of HLA antibodies on survival after transplant and the development of BOS were determined using Cox models. RESULTS: Of the 441 recipients, 139 (32%) had detectable antibodies to HLA. Of these 139, 54 (39%) developed antibodies specific to donor HLA. The detection of posttransplant HLA antibodies was associated with BOS (HR, 1.54; P=.04) and death (HR, 1.53; P=.02) in multivariable models. The detection of donor-specific HLA antibodies was associated with death (HR, 2.42; P<.0001). The detection of posttransplant HLA antibodies was associated with pretransplant HLA-antibody detection, platelet transfusions, and the development of BOS and cytomegalovirus pneumonitis. CONCLUSIONS: Approximately one-third of lung transplant recipients have detectable HLA antibodies, which are associated with a worse prognosis regarding graft function and patient survival. SN - 1931-3543 UR - https://www.unboundmedicine.com/medline/citation/23328795/Implications_for_human_leukocyte_antigen_antibodies_after_lung_transplantation:_a_10_year_experience_in_441_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(13)60471-7 DB - PRIME DP - Unbound Medicine ER -